IQVIQV
Buy moreBuy more on a dip to our buy price, which is under today's $271.
- 4 good· Earnings beat
- 1 to watch· Growing slower than rivals
$271.06−3.47 (−1.26%)
Price at 3:03 PM ET
After hours · opens in 17h 23mNext open: Friday, Nov 13, 9:30 AM ETHealthcare · Large company
The price we'd buy IQV at comes with a free account
It also has the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.
What would change it
Sources
- From the 10-Q for the quarter to Sep 30, reported Oct 27
- Yahoo Finance daily closes to Nov 9
Any one could move it to Keep
Next report
Shrinking
sales
Compared with the S&P 500
7 points
worse in one day
16 points
worse in five trading days
+27.2% in a yearsince Nov 10, 2025
The news behind our call
written Aug 19, 7:21 AM ETAug 19, 7:21 AM ET · 1 articles · 1 sources
Received a score of 96.8 out of 100.
- IQVIA’s top Everest Group ranking strengthens its credibility with pharmaceutical companies.
Healthcare is attracting stronger market participation during the correction.
What changed
From Scheduled market snapshot and Yahoo Finance
Overview
In plain numbers
- Revenue grew 8.8% from a year earlier, to $17.3B in the last twelve months.
- It keeps 14 cents of every revenue dollar as operating profit, up from 10 cents in FY 2021.
- It turned 12% of revenue into free cash flow: $2.1B in the last twelve months.
- It owes $16.3B and holds $2.4B in cash and investments, so net debt is $13.9B.
Key figures
- Revenue (TTM)
- $17.3B
- Revenue growth, 1 year
- +8.8%
- Net income
- $1.4B
- EPS (diluted)
- $8.25
- Gross margin
- 33.1%
- Operating margin
- 13.9%
- Return on equity
- 21.4%
- Return on capital
- 9.9%
- Debt / equity
- 2.40
- Current ratio
- 0.83
- Buyback yield
- 3.88%
Key facts
- Company value
- $44.8B
- Price / last year's earnings
- 29.9×
- Today's range
- 266.23274.26
- Past year's range
- 156.66279.40
- Yesterday's close
- $274.53
- Swings vs the market
- 1.2×about the same